drugset / Trial / NCT05191680
TherApeutics in Early ProState Cancer (TAPS02)
Phase 2
Recruiting
90 enrolled
Cambridge University Hospitals NHS Foundation Trust
Janssen-Cilag Ltd. · collabUniversity of Cambridge · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a phase 2, randomised, multicentre, double-blind, placebo-controlled trial investigating the use of short term androgen deprivation therapy in the form of apalutamide (Erleada) in men on active surveillance for prostate cancer.
Timeline
- Start
- 2023-04-24
- Primary completion
- 2029-10
- Completion
- 2029-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Apalutamide | Small molecule | 240 mg | Oral |